| Title : Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes - Cheng_2008_J.Pharmacol.Exp.Ther_327_683 |
| Author(s) : Cheng Q , Law PK , de Gasparo M , Leung PS |
| Ref : Journal of Pharmacology & Experimental Therapeutics , 327 :683 , 2008 |
| Abstract : Cheng_2008_J.Pharmacol.Exp.Ther_327_683 |
| ESTHER : Cheng_2008_J.Pharmacol.Exp.Ther_327_683 |
| PubMedSearch : Cheng_2008_J.Pharmacol.Exp.Ther_327_683 |
| PubMedID: 18787107 |
Cheng Q, Law PK, de Gasparo M, Leung PS (2008)
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes
Journal of Pharmacology & Experimental Therapeutics
327 :683
Cheng Q, Law PK, de Gasparo M, Leung PS (2008)
Journal of Pharmacology & Experimental Therapeutics
327 :683